EarningsQ3 2026 Earnings Report
MX:MRUN Q3 2026 EPS Results
Actual EPS$15.30
Consensus EPS$15.29
Beat/MissBeat by +$0.01
One Year Ago EPS$18.75
MX:MRUN Q3 2026 Revenue Results
Actual Revenue$86.00B
Expected Revenue$85.14B
Beat/MissBeat by +$852.67M
YoY Revenue Growth+1.45%
Earnings Announcement Details
QuarterQ3 2026
Date08/12/2026
TimeBefore Open
Conference CallWednesday, August 12, 2026
MX:MRUN Upcoming Earnings
Metro Inc.'s next earnings date is estimated for November 25, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The quarter shows a mix of clear operational headwinds and resilient long-term growth drivers. Near-term performance was materially affected by a labour strike that erased margin and profit and pressured same-store sales and EBITDA margins. Offsetting factors include strong pharmacy momentum (prescription growth, GLP-1 adoption), robust e-commerce growth (+16.3%), active network optimization with expected medium-term benefits (~$15M after-tax annually), continued retail expansion and a sizable share buyback program. Given the significant but (management describes) temporary strike-related impact alongside credible actions to improve network efficiency and long‑term growth in pharmacy and e-commerce, the positives and negatives are roughly balanced.Company Guidance
Top-line Growth
Total sales of $6.97 billion, up 1.4% year-over-year, driven by new store openings and growth in pharmacy and online channels.
Pharmacy Momentum
Pharmacy total sales up 5.0% with same-store sales +4.8%; prescription sales +6.4%. Two-year stacked growth: prescriptions +13% and commercial front-store +5.5%.
E-commerce Expansion
Online sales grew 16.3% in the quarter, driven by third-party marketplaces, click-and-collect ramp-up and expanded delivery in discount banners.
Network Optimization & Strategic Transaction
Announced conversion of 10 Metro stores to Food Basics, shift from a Montreal dark store to store-based fulfillment and a strategic partnership to sell Première Moisson's production facility for $90 million. These initiatives incurred non‑recurring charges but are expected to generate an estimated recurring annual after-tax benefit of ~$15 million by end of fiscal 2028 (about half by end of fiscal 2027).
Retail Investment Progress
Q3 CapEx $167.3 million (vs $145.5M prior year); opened 5 new discount stores in quarter and remain on track to open ~12 discount stores by fiscal year-end; net retail network square footage up 245,000 sq ft (1.1%).
Share Repurchase Activity
Under the NCIB program repurchased 4.9 million shares for $463.1 million at an average price of $94.56, reflecting active capital allocation.
GLP-1 Category Opportunity
Despite generic semaglutide-induced price deflation, the GLP-1 category is showing increased patient adoption and higher prescription volumes; company expects low‑teens contribution growth (volume-driven) for the category and low-single-digit sales growth.
Adjusted Results in Line with Guidance
Adjusted EPS of $1.24 for Q3 was within the guidance provided at the time of the June update.
MX:MRUN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed